Long-term results of Nivolumab + Cabozantinib in RCC

Published Date: 08 Mar 2023

The combination of first-line nivolumab and cabozantinib continues to outperform sunitinib in the treatment of patients with advanced renal cell carcinoma (RCC).

Read Full News

Latest News



Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Bridging the Gap to CAR T-Cell Therapy for Relapsed/Refractory Multiple Myeloma: An Expert TheraTalk

2.

"A lot" of aspirin reduces the risk of ovarian cancer, regardless of genetic factors, according to the JAMA study.

3.

Woman Loses 6-Year Battle With Mouth Tumor

4.

Q&A: Researchers discuss identifying potential new protein targets for melanoma therapeutics

5.

Housing aid linked to lower medical financial hardship among US renters with cancer


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot